英菲格拉替尼副作用多不多？治疗时要注意什么

Infigratinib is a kinase inhibitor indicated for the treatment of adult patients with previously treated, unresectable locally advanced or metastatic FGFR2 fusion cholangiocarcinoma. Clinical trial results show that infigratinib can prolong the survival period of patients, increase the remission rate, improve the quality of life of patients, reduce the pain of patients, and have a positive effect on the patient's condition. However, patients cannot blindly use this drug for treatment, because use will also produce some side effects. Does Infigratinib have many side effects? What should I pay attention to during treatment?

Infigratinib side effects include: nail toxicity, stomatitis, dry eye syndrome, fatigue, hair loss, palmoplantar erythema syndrome, joint pain, dysgeusia, constipation, abdominal pain, dry mouth, eyelash changes, diarrhea, dry skin, loss of appetite, blurred vision, vomiting, etc. Because each patient's disease progression and tolerance to drugs are different, the side effects, severity, and severity of side effects after treatment with the drug are different and cannot be generalized. The number of side effects is mainly determined by the patient's own situation. If a patient has a serious adverse reaction during treatment with Infigratinib, he or she should go to the hospital immediately and receive formal treatment from a professional doctor. Patients cannot blindly use other drugs for treatment to avoid more adverse reactions.

Infigratinib Precautions

Treatment with Infigratinib may cause harm to the fetus, so pregnant women should not use this drug for treatment and should inform their doctor whether they are pregnant before receiving this drug. Women of childbearing potential should use appropriate contraception while receiving Infigratinib. Breastfeeding patients should stop taking the drug or breastfeeding immediately.

Treatment with Infigratinib may result in hyperphosphatemia and soft tissue mineralization, which, depending on the severity, may require consideration of discontinuation, dose reduction, or permanent discontinuation.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related articles: